Eintrag weiter verarbeiten
Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance
Gespeichert in:
| Zeitschriftentitel: | Molecular Cancer Therapeutics |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , , , , |
| In: | Molecular Cancer Therapeutics, 17, 2018, 11, S. 2285-2296 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Association for Cancer Research (AACR)
|
| Schlagwörter: |
| author_facet |
Quanz, Maria Bender, Eckhard Kopitz, Charlotte Grünewald, Sylvia Schlicker, Andreas Schwede, Wolfgang Eheim, Ashley Toschi, Luisella Neuhaus, Roland Richter, Carmen Toedling, Joern Merz, Claudia Lesche, Ralf Kamburov, Atanas Siebeneicher, Holger Bauser, Marcus Hägebarth, Andrea Quanz, Maria Bender, Eckhard Kopitz, Charlotte Grünewald, Sylvia Schlicker, Andreas Schwede, Wolfgang Eheim, Ashley Toschi, Luisella Neuhaus, Roland Richter, Carmen Toedling, Joern Merz, Claudia Lesche, Ralf Kamburov, Atanas Siebeneicher, Holger Bauser, Marcus Hägebarth, Andrea |
|---|---|
| author |
Quanz, Maria Bender, Eckhard Kopitz, Charlotte Grünewald, Sylvia Schlicker, Andreas Schwede, Wolfgang Eheim, Ashley Toschi, Luisella Neuhaus, Roland Richter, Carmen Toedling, Joern Merz, Claudia Lesche, Ralf Kamburov, Atanas Siebeneicher, Holger Bauser, Marcus Hägebarth, Andrea |
| spellingShingle |
Quanz, Maria Bender, Eckhard Kopitz, Charlotte Grünewald, Sylvia Schlicker, Andreas Schwede, Wolfgang Eheim, Ashley Toschi, Luisella Neuhaus, Roland Richter, Carmen Toedling, Joern Merz, Claudia Lesche, Ralf Kamburov, Atanas Siebeneicher, Holger Bauser, Marcus Hägebarth, Andrea Molecular Cancer Therapeutics Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance Cancer Research Oncology |
| author_sort |
quanz, maria |
| spelling |
Quanz, Maria Bender, Eckhard Kopitz, Charlotte Grünewald, Sylvia Schlicker, Andreas Schwede, Wolfgang Eheim, Ashley Toschi, Luisella Neuhaus, Roland Richter, Carmen Toedling, Joern Merz, Claudia Lesche, Ralf Kamburov, Atanas Siebeneicher, Holger Bauser, Marcus Hägebarth, Andrea 1535-7163 1538-8514 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1535-7163.mct-17-1253 <jats:title>Abstract</jats:title> <jats:p>The lactate transporter SLC16A1/monocarboxylate transporter 1 (MCT1) plays a central role in tumor cell energy homeostasis. In a cell-based screen, we identified a novel class of MCT1 inhibitors, including BAY-8002, which potently suppress bidirectional lactate transport. We investigated the antiproliferative activity of BAY-8002 in a panel of 246 cancer cell lines and show that hematopoietic tumor cells, in particular diffuse large B-cell lymphoma cell lines, and subsets of solid tumor models are particularly sensitive to MCT1 inhibition. Associated markers of sensitivity were, among others, lack of MCT4 expression, low pleckstrin homology like domain family A member 2, and high pellino E3 ubiquitin protein ligase 1 expression. The antitumor effect of MCT1 inhibition was less pronounced on tumor xenografts, with tumor stasis being the maximal response. BAY-8002 significantly increased intratumor lactate levels and transiently modulated pyruvate levels. In order to address potential acquired resistance mechanisms to MCT1 inhibition, we generated MCT1 inhibitor–resistant cell lines and show that resistance can occur by upregulation of MCT4 even in the presence of sufficient oxygen, as well as by shifting energy generation toward oxidative phosphorylation. These findings provide insight into novel aspects of tumor response to MCT1 modulation and offer further rationale for patient selection in the clinical development of MCT1 inhibitors. Mol Cancer Ther; 17(11); 2285–96. ©2018 AACR.</jats:p> Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance Molecular Cancer Therapeutics |
| doi_str_mv |
10.1158/1535-7163.mct-17-1253 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xNTM1LTcxNjMubWN0LTE3LTEyNTM |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xNTM1LTcxNjMubWN0LTE3LTEyNTM |
| institution |
DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 |
| imprint |
American Association for Cancer Research (AACR), 2018 |
| imprint_str_mv |
American Association for Cancer Research (AACR), 2018 |
| issn |
1535-7163 1538-8514 |
| issn_str_mv |
1535-7163 1538-8514 |
| language |
English |
| mega_collection |
American Association for Cancer Research (AACR) (CrossRef) |
| match_str |
quanz2018preclinicalefficacyofthenovelmonocarboxylatetransporter1inhibitorbay8002andassociatedmarkersofresistance |
| publishDateSort |
2018 |
| publisher |
American Association for Cancer Research (AACR) |
| recordtype |
ai |
| record_format |
ai |
| series |
Molecular Cancer Therapeutics |
| source_id |
49 |
| title |
Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance |
| title_unstemmed |
Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance |
| title_full |
Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance |
| title_fullStr |
Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance |
| title_full_unstemmed |
Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance |
| title_short |
Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance |
| title_sort |
preclinical efficacy of the novel monocarboxylate transporter 1 inhibitor bay-8002 and associated markers of resistance |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1158/1535-7163.mct-17-1253 |
| publishDate |
2018 |
| physical |
2285-2296 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>The lactate transporter SLC16A1/monocarboxylate transporter 1 (MCT1) plays a central role in tumor cell energy homeostasis. In a cell-based screen, we identified a novel class of MCT1 inhibitors, including BAY-8002, which potently suppress bidirectional lactate transport. We investigated the antiproliferative activity of BAY-8002 in a panel of 246 cancer cell lines and show that hematopoietic tumor cells, in particular diffuse large B-cell lymphoma cell lines, and subsets of solid tumor models are particularly sensitive to MCT1 inhibition. Associated markers of sensitivity were, among others, lack of MCT4 expression, low pleckstrin homology like domain family A member 2, and high pellino E3 ubiquitin protein ligase 1 expression. The antitumor effect of MCT1 inhibition was less pronounced on tumor xenografts, with tumor stasis being the maximal response. BAY-8002 significantly increased intratumor lactate levels and transiently modulated pyruvate levels. In order to address potential acquired resistance mechanisms to MCT1 inhibition, we generated MCT1 inhibitor–resistant cell lines and show that resistance can occur by upregulation of MCT4 even in the presence of sufficient oxygen, as well as by shifting energy generation toward oxidative phosphorylation. These findings provide insight into novel aspects of tumor response to MCT1 modulation and offer further rationale for patient selection in the clinical development of MCT1 inhibitors. Mol Cancer Ther; 17(11); 2285–96. ©2018 AACR.</jats:p> |
| container_issue |
11 |
| container_start_page |
2285 |
| container_title |
Molecular Cancer Therapeutics |
| container_volume |
17 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792347213188300811 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:51:26.914Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Preclinical+Efficacy+of+the+Novel+Monocarboxylate+Transporter+1+Inhibitor+BAY-8002+and+Associated+Markers+of+Resistance&rft.date=2018-11-01&genre=article&issn=1538-8514&volume=17&issue=11&spage=2285&epage=2296&pages=2285-2296&jtitle=Molecular+Cancer+Therapeutics&atitle=Preclinical+Efficacy+of+the+Novel+Monocarboxylate+Transporter+1+Inhibitor+BAY-8002+and+Associated+Markers+of+Resistance&aulast=H%C3%A4gebarth&aufirst=Andrea&rft_id=info%3Adoi%2F10.1158%2F1535-7163.mct-17-1253&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792347213188300811 |
| author | Quanz, Maria, Bender, Eckhard, Kopitz, Charlotte, Grünewald, Sylvia, Schlicker, Andreas, Schwede, Wolfgang, Eheim, Ashley, Toschi, Luisella, Neuhaus, Roland, Richter, Carmen, Toedling, Joern, Merz, Claudia, Lesche, Ralf, Kamburov, Atanas, Siebeneicher, Holger, Bauser, Marcus, Hägebarth, Andrea |
| author_facet | Quanz, Maria, Bender, Eckhard, Kopitz, Charlotte, Grünewald, Sylvia, Schlicker, Andreas, Schwede, Wolfgang, Eheim, Ashley, Toschi, Luisella, Neuhaus, Roland, Richter, Carmen, Toedling, Joern, Merz, Claudia, Lesche, Ralf, Kamburov, Atanas, Siebeneicher, Holger, Bauser, Marcus, Hägebarth, Andrea, Quanz, Maria, Bender, Eckhard, Kopitz, Charlotte, Grünewald, Sylvia, Schlicker, Andreas, Schwede, Wolfgang, Eheim, Ashley, Toschi, Luisella, Neuhaus, Roland, Richter, Carmen, Toedling, Joern, Merz, Claudia, Lesche, Ralf, Kamburov, Atanas, Siebeneicher, Holger, Bauser, Marcus, Hägebarth, Andrea |
| author_sort | quanz, maria |
| container_issue | 11 |
| container_start_page | 2285 |
| container_title | Molecular Cancer Therapeutics |
| container_volume | 17 |
| description | <jats:title>Abstract</jats:title> <jats:p>The lactate transporter SLC16A1/monocarboxylate transporter 1 (MCT1) plays a central role in tumor cell energy homeostasis. In a cell-based screen, we identified a novel class of MCT1 inhibitors, including BAY-8002, which potently suppress bidirectional lactate transport. We investigated the antiproliferative activity of BAY-8002 in a panel of 246 cancer cell lines and show that hematopoietic tumor cells, in particular diffuse large B-cell lymphoma cell lines, and subsets of solid tumor models are particularly sensitive to MCT1 inhibition. Associated markers of sensitivity were, among others, lack of MCT4 expression, low pleckstrin homology like domain family A member 2, and high pellino E3 ubiquitin protein ligase 1 expression. The antitumor effect of MCT1 inhibition was less pronounced on tumor xenografts, with tumor stasis being the maximal response. BAY-8002 significantly increased intratumor lactate levels and transiently modulated pyruvate levels. In order to address potential acquired resistance mechanisms to MCT1 inhibition, we generated MCT1 inhibitor–resistant cell lines and show that resistance can occur by upregulation of MCT4 even in the presence of sufficient oxygen, as well as by shifting energy generation toward oxidative phosphorylation. These findings provide insight into novel aspects of tumor response to MCT1 modulation and offer further rationale for patient selection in the clinical development of MCT1 inhibitors. Mol Cancer Ther; 17(11); 2285–96. ©2018 AACR.</jats:p> |
| doi_str_mv | 10.1158/1535-7163.mct-17-1253 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xNTM1LTcxNjMubWN0LTE3LTEyNTM |
| imprint | American Association for Cancer Research (AACR), 2018 |
| imprint_str_mv | American Association for Cancer Research (AACR), 2018 |
| institution | DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275 |
| issn | 1535-7163, 1538-8514 |
| issn_str_mv | 1535-7163, 1538-8514 |
| language | English |
| last_indexed | 2024-03-01T17:51:26.914Z |
| match_str | quanz2018preclinicalefficacyofthenovelmonocarboxylatetransporter1inhibitorbay8002andassociatedmarkersofresistance |
| mega_collection | American Association for Cancer Research (AACR) (CrossRef) |
| physical | 2285-2296 |
| publishDate | 2018 |
| publishDateSort | 2018 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | ai |
| recordtype | ai |
| series | Molecular Cancer Therapeutics |
| source_id | 49 |
| spelling | Quanz, Maria Bender, Eckhard Kopitz, Charlotte Grünewald, Sylvia Schlicker, Andreas Schwede, Wolfgang Eheim, Ashley Toschi, Luisella Neuhaus, Roland Richter, Carmen Toedling, Joern Merz, Claudia Lesche, Ralf Kamburov, Atanas Siebeneicher, Holger Bauser, Marcus Hägebarth, Andrea 1535-7163 1538-8514 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1535-7163.mct-17-1253 <jats:title>Abstract</jats:title> <jats:p>The lactate transporter SLC16A1/monocarboxylate transporter 1 (MCT1) plays a central role in tumor cell energy homeostasis. In a cell-based screen, we identified a novel class of MCT1 inhibitors, including BAY-8002, which potently suppress bidirectional lactate transport. We investigated the antiproliferative activity of BAY-8002 in a panel of 246 cancer cell lines and show that hematopoietic tumor cells, in particular diffuse large B-cell lymphoma cell lines, and subsets of solid tumor models are particularly sensitive to MCT1 inhibition. Associated markers of sensitivity were, among others, lack of MCT4 expression, low pleckstrin homology like domain family A member 2, and high pellino E3 ubiquitin protein ligase 1 expression. The antitumor effect of MCT1 inhibition was less pronounced on tumor xenografts, with tumor stasis being the maximal response. BAY-8002 significantly increased intratumor lactate levels and transiently modulated pyruvate levels. In order to address potential acquired resistance mechanisms to MCT1 inhibition, we generated MCT1 inhibitor–resistant cell lines and show that resistance can occur by upregulation of MCT4 even in the presence of sufficient oxygen, as well as by shifting energy generation toward oxidative phosphorylation. These findings provide insight into novel aspects of tumor response to MCT1 modulation and offer further rationale for patient selection in the clinical development of MCT1 inhibitors. Mol Cancer Ther; 17(11); 2285–96. ©2018 AACR.</jats:p> Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance Molecular Cancer Therapeutics |
| spellingShingle | Quanz, Maria, Bender, Eckhard, Kopitz, Charlotte, Grünewald, Sylvia, Schlicker, Andreas, Schwede, Wolfgang, Eheim, Ashley, Toschi, Luisella, Neuhaus, Roland, Richter, Carmen, Toedling, Joern, Merz, Claudia, Lesche, Ralf, Kamburov, Atanas, Siebeneicher, Holger, Bauser, Marcus, Hägebarth, Andrea, Molecular Cancer Therapeutics, Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance, Cancer Research, Oncology |
| title | Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance |
| title_full | Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance |
| title_fullStr | Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance |
| title_full_unstemmed | Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance |
| title_short | Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance |
| title_sort | preclinical efficacy of the novel monocarboxylate transporter 1 inhibitor bay-8002 and associated markers of resistance |
| title_unstemmed | Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1158/1535-7163.mct-17-1253 |